Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA, showing good bioavailability and predictable serum levels of subcutaneously administered BiTE(R) antibodies(1). BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.

Micromet conducted a pharmacokinetic study in non-human primates exploring different routes of administration of its BiTE antibody MT110, which is targeting EpCAM (CD326) and is the most advanced BiTE antibody with potential application for the treatment of solid tumors. Continuous intravenous administration, as currently used in an ongoing phase 1 clinical trial with MT103 (MEDI-538), was compared to subcutaneous administration by daily repeated bolus injection and continuous administration using mini-pumps, which are commercially available and routinely used by patients with diabetes for the delivery of insulin. Both subcutaneous regimens resulted in bioavailability of MT110 of 30 to 40 percent, with constant serum trough levels over the six-day treatment period.

"Our pre-clinical results are paving the way for the development of alternative routes of administration for MT110 and other BiTE antibodies to further enhance the quality of life of patients under treatment," comments Patrick A. Baeuerle, Micromet's chief scientific officer. "A very convenient mini-pump system, designed for life-long use by diabetes patients for ins
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)...  IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey ... the first quarter ended March 31, 2015. First ... million in the first quarter of 2015, an increase of ... net revenues generated from the sale of IGI label generic ... 2015 and 2014 of $8.1 million, and $2.9 million, respectively ...
(Date:4/28/2015)... Mass. , April 28, 2015 Merrimack Pharmaceuticals, ... will hold its First Quarter 2015 Investor Conference Call and ... 2015.  Merrimack also announced it will present at the Credit ... 10:55 a.m., Eastern Time, in New York ... The call will cover an update on Merrimack,s ...
(Date:4/28/2015)... -- Perrigo Company plc (NYSE: PRGO ; TASE) today ... dividend of $0.125 per share, payable on June 16, 2015 ... From its beginnings as a packager of ... in Ireland , has grown to ... and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, ...
Breaking Medicine Technology:IGI Laboratories Announces First Quarter 2015 Results 2IGI Laboratories Announces First Quarter 2015 Results 3IGI Laboratories Announces First Quarter 2015 Results 4IGI Laboratories Announces First Quarter 2015 Results 5IGI Laboratories Announces First Quarter 2015 Results 6IGI Laboratories Announces First Quarter 2015 Results 7IGI Laboratories Announces First Quarter 2015 Results 8IGI Laboratories Announces First Quarter 2015 Results 9IGI Laboratories Announces First Quarter 2015 Results 10IGI Laboratories Announces First Quarter 2015 Results 11Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference 2
... Transcript Pharmacy has been awarded accreditation status by the ... pharmacy services.   "This recognition demonstrates that ... offer bring significant benefits to the patients that we ... private, not-for-profit corporation which is certified to ISO 9001:2008 ...
... OAKS, Calif., Oct. 20 Amgen (Nasdaq: AMGN ... quarter financial results on Monday, Oct. 25, 2010 after the ... by a conference call with the investment community at 2 ... be Kevin Sharer, chairman and chief executive officer, and other ...
Cached Medicine Technology:Transcript Pharmacy Awarded Accreditation by ACHC 2Amgen Announces Webcast of 2010 Third Quarter Financial Results 2
(Date:4/28/2015)... (PRWEB) April 28, 2015 Aultman ... Care Advantage (WCA) to transition its outpatient wound ... the hospital’s commitment to the specialty of wound ... across the country currently working with Wound ... offers advanced wound care treatments and hyperbaric oxygen ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Children’s ... advances the cause of medical foods and formulas ... Childress as the organization’s new executive director. , ... severe health consequences because of conditions and diseases ... life-sustaining diet. To live and thrive, they ...
(Date:4/28/2015)... 2015 Market Research Report on Global ... in-depth research report. The report provides information such ... chain structure, international market analysis, and China’s domestic ... Europe, Japan, Asia) and Chinese market as well ... situation analysis. The Global and Chinese Centrifuges Industry ...
(Date:4/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation ... to call an attorney before calling the ICBC in ... that there are several benefits of hiring a personal ... law and can help clients reach a better settlement ... own. Competent and experienced personal injury lawyers help their ...
(Date:4/28/2015)... MSA Executive Search , an INTEGRATED ... that it has been retained to lead a nationwide ... for The Queen's Health Systems (QHS) located in ... & CEO Arthur A. Ushijima, the Executive Vice President ... the Queen’s Medical Center Punchbowl and West O’ahu sites, ...
Breaking Medicine News(10 mins):Health News:Aultman Hospital Transitions Electronic Medical Record for Wound Center with Wound Care Advantage 2Health News:Aultman Hospital Transitions Electronic Medical Record for Wound Center with Wound Care Advantage 3Health News:Children's Medical Nutrition Alliance (CMNuA) Hires Kaycee Childress as Executive Director 2Health News:Centrifuges Market 2015 Global Research Report 2Health News:Centrifuges Market 2015 Global Research Report 3Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:The Queen’s Health Systems Retains MSA Executive Search to Recruit Executive Vice President & Chief Operating Officer 2
... 10,000 pediatricians,and other health care professionals are expected to ... and Exhibition (NCE),at the Hynes Convention Center in Boston., ... 12, 11:50 a.m.-12:10 p.m., The ABC Ballroom at ... a huge recording studio as over 2,500,pediatricians get to ...
... WASHINGTON, Oct. 8 Give an Hour, a,non-partisan, ... veterans and their loved ones, announces a collaboration ... used by thousands,of consumers nationwide to locate needed ... agreement, mental health professionals, who join the Give,an ...
... Northwestern Memorial,s Bluhm Cardiovascular Institute is one of ... aimed at improving the heart,s pumping action and helping ... trial tests the effectiveness of placing a small device ... the heart. Northwestern Memorial physicians recently implanted the first ...
... 300 million cases of the disease each year , , WEDNESDAY, ... malaria-causing Plasmodium vivax parasite has been described by ... help in the fight against malaria. , The majority of ... parasite, which causes the most virulent form of the ...
... ALEXANDRIA, Va., Oct, 8 The National,Community Pharmacists ... one-term incumbent representing Minnesota, for re-election to the,U.S. ... CEO of NCPA,issued the following statement:, "Senator ... and,America,s community pharmacies and the patients they serve. ...
... The National,Community Pharmacists Association (NCPA) is endorsing Sen. ... re-election to the,U.S. Senate. Bruce Roberts, RPh, executive ... statement:, "Senator Richard Durbin is a powerful ... patients they serve. That is why the,National Community ...
Cached Medicine News:Health News:AAP National Conference and Exhibition October 10-14, 2008 2Health News:AAP National Conference and Exhibition October 10-14, 2008 3Health News:HelpPRO and Give an Hour Join to Help Military Families Get Free Therapy Services 2Health News:Northwestern Memorial trials implantable device to manage congestive heart failure symptoms 2Health News:Genetic Research Offers Insights Into Form of Malaria 2
... QuadraLase™ is a unique lateral ... that may be rotated to ... like having four fibers in ... used for vaporization and coagulation ...
... Graft with the H&L-B One-Shot Introduction System ... endovascular treatment of patients with abdominal aortic ... endovascular repair. The Zenith AAA Endovascular Graft ... to "seal off" the aneurysm. The graft ...
... The Ultrafin™ Stirrup is ... positioing. This stirrup features a ... and accommodates up to an ... technology helps to position heavy ...
Stirrups provide a safe system for positioning patients in a variety of lithotomy positions. Power-assisted positioning, as well as abduction, assures proper positioning of the patient. Includes one ...
Medicine Products: